Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $12.77

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average recommendation of “Buy” by the fourteen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $12.7692.

A number of analysts have issued reports on TSHA shares. Robert W. Baird lifted their target price on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. The Goldman Sachs Group increased their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. BMO Capital Markets raised their price target on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Citizens Jmp reaffirmed a “market outperform” rating and issued a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Wednesday, June 24th.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $5.52 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies has a fifty-two week low of $2.53 and a fifty-two week high of $7.30. The stock’s 50-day moving average is $5.97 and its two-hundred day moving average is $5.37. The firm has a market cap of $1.59 billion, a P/E ratio of -14.53 and a beta of 1.17.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Analysts predict that Taysha Gene Therapies will post -0.49 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the sale, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP grew its holdings in Taysha Gene Therapies by 150.0% during the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after purchasing an additional 8,250,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Taysha Gene Therapies by 2.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock worth $75,310,000 after buying an additional 309,031 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Taysha Gene Therapies by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after buying an additional 418,192 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares during the period. Finally, State Street Corp boosted its holdings in shares of Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after buying an additional 3,553,619 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.